13. A pharmaceutical composition, comprising at least one compound according to any one of claims 1 to 12 and/or pharmaceutically acceptable salts or stereoisomers thereof, and a pharmaceutically acceptable carrier or excipient.

14. A compound according to any one of claims 1 to 12, or pharmaceutically acceptable salts or stereoisomers thereof, for use as a medicament.

15. A compound according to any one of claims 1 to 12, or pharmaceutically acceptable salts or stereoisomers thereof, for use as a medicament, for the treatment of cancer or for inhibiting anaplastic lymphoma kinase (ALK).

~~16. A method of treating cancer, the method comprising: administering to a subject an effective amount of the compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13.~~

~~17. The method of claim 16, wherein the subject has a cancer that expresses an oncogenic ALK.~~

~~18. The method of claim 17, wherein the ALK fusion protein is EML4-ALK fusion protein or NPM-ALK fusion protein or any other disease causing ALK fusion protein.~~

~~19. The method of claim 16, wherein the cancer is selected from adenocarcinoma, lung cancer, non-small cell lung carcinoma, breast cancer, colorectal cancer, lymphoma, neuroblastoma, ovarian cancer, mesothelioma, melanoma, glioblastoma, diffuse large B-cell lymphomas, systemic histiocytosis, or inflammatory myofibroblastic tumors.~~

~~20. A method of treating a condition where it is desired to inhibit ALK activity, comprising administering to a subject an effective amount of the compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13.~~

16~~21~~. The compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13 for use in treating cancer, wherein the cancer expresses an ALK oncogene.